EDITORIAL Arrhythmic Risk Stratification for Arrhythmogenic Right Ventricular Cardiomyopathy Should We Ask Who Is at High Risk or Who Is at Low Risk? See Article by Orgeron et al Julia H. Indik, MD, PhD rrhythmogenic right ventricular cardiomyopathy (ARVC) is a progressive disorder characterized by morphological changes in the myocardium that Aplace the patient at risk for lethal ventricular arrhythmias. A genetic muta- tion involving desmosomes is seen in most patients that affects myocyte cell-to- cell adhesion. Athletes are likely to express this disease at an earlier age as exercise promotes progression of the disease. Because either ventricle can be affected, the 1,2 term arrhythmogenic cardiomyopathy has been proposed. Diagnosis is based on criteria as set out in the 2010 Task Force document, encompassing ventricular structure, histology, electrocardiographic features, arrhythmias, and genetic fea- tures. In 2015, an International Task Force published a consensus statement to pro- vide clinical practice guidance based on available evidence and expert opinion. For implantable cardioverter defibrillator (ICD) implantation, the Task Force as- signed a class I recommendation to patients who had been resuscitated from he- modynamically unstable ventricular tachycardia (VT) or ventricular fibrillation (VF) and for patients with severe right ventricular or left ventricular systolic
Circulation: Arrhythmia & Electrophysiology – Wolters Kluwer Health
Published: Feb 1, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
It’s easy to organize your research with our built-in tools.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud